CDK9 modulating compounds for cancer therapy
Summary
The European Patent Office granted patent EP3873911A1 to Kronos Bio, Inc. covering CDK9 modulating compounds and compositions for cancer therapy. The patent lists inventors Mikochik, Vacca, Freeman, and Tasker, with protection extending to 38 designated European states. This IP protection covers pyrrolopyridine and pyrazolopyridine derivatives targeting CDK9 for oncology applications.
What changed
The European Patent Office published patent application EP3873911A1 for Kronos Bio's CDK9 modulating compounds, compositions, and methods for treating cancer. The patent covers pyrrolopyridine and pyrazolopyridine derivative compounds that inhibit CDK9 activity, a cyclin-dependent kinase implicated in cancer cell proliferation. The patent application was filed with claims spanning multiple EPC contracting states.
Pharmaceutical companies and biotech firms developing CDK9 inhibitors or pursuing oncology research programs should conduct freedom-to-operate analyses to assess potential patent infringement risks. Generic drug manufacturers and research institutions may find opportunities to license the technology or explore design-around strategies for their own compound development efforts.
What to do next
- Review patent claims for freedom-to-operate implications if developing CDK9 inhibitors
- Monitor for corresponding national validations in target markets
- Consider licensing opportunities for the patented technology
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY
Publication EP3873911A1 Kind: A1 Apr 01, 2026
Applicants
Kronos Bio, Inc.
Inventors
MIKOCHIK, Peter, VACCA, Joseph, FREEMAN, David, TASKER, Andrew
IPC Classifications
C07D 487/04 20060101AFI20220519BHEP A61K 31/519 20060101ALI20220519BHEP A61P 35/00 20060101ALI20220519BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.